ATE530657T1 - Verfahren zur herstellung von zellinien mit latentem immunschwächevirus - Google Patents

Verfahren zur herstellung von zellinien mit latentem immunschwächevirus

Info

Publication number
ATE530657T1
ATE530657T1 AT02797433T AT02797433T ATE530657T1 AT E530657 T1 ATE530657 T1 AT E530657T1 AT 02797433 T AT02797433 T AT 02797433T AT 02797433 T AT02797433 T AT 02797433T AT E530657 T1 ATE530657 T1 AT E530657T1
Authority
AT
Austria
Prior art keywords
immunodeficiency virus
latent
invention further
further provides
cell lines
Prior art date
Application number
AT02797433T
Other languages
English (en)
Inventor
Eric Verdin
Albert Jordan
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of ATE530657T1 publication Critical patent/ATE530657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02797433T 2001-12-19 2002-12-18 Verfahren zur herstellung von zellinien mit latentem immunschwächevirus ATE530657T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34172701P 2001-12-19 2001-12-19
PCT/US2002/040698 WO2003054160A2 (en) 2001-12-19 2002-12-18 Cell lines with latent immunodeficiency virus and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE530657T1 true ATE530657T1 (de) 2011-11-15

Family

ID=23338764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797433T ATE530657T1 (de) 2001-12-19 2002-12-18 Verfahren zur herstellung von zellinien mit latentem immunschwächevirus

Country Status (5)

Country Link
US (3) US7232685B2 (de)
EP (1) EP1463822B1 (de)
AT (1) ATE530657T1 (de)
AU (1) AU2002361797A1 (de)
WO (1) WO2003054160A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303953B2 (en) * 2002-09-10 2007-10-04 Microbiotix, Inc. Antibacterial pyrazole carboxylic acid hydrazides
CN1301263C (zh) * 2002-12-18 2007-02-21 北京昭衍新药研究中心 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
WO2006019841A2 (en) * 2004-07-13 2006-02-23 Government Of The United States Of America Treatment of viral infections with egr 1 activators
WO2006029029A2 (en) * 2004-09-02 2006-03-16 The Uab Research Foundation Compositions for detection of latent hiv reactivation and methods of using the same
CA2632456C (en) * 2005-12-05 2016-06-21 Joseph P. Dougherty An hiv-1 latency model for high throughput screening
EP2010680A2 (de) * 2006-04-14 2009-01-07 Tibotec Pharmaceuticals Ltd. Verfahren und mittel zur beurteilung von hiv-gag-/proteasehemmer-therapie
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
JP5779503B2 (ja) * 2008-10-29 2015-09-16 イスティチュート スペリオーレ ディ サニータ 酸化ストレスを用いるレトロウイルスレゼルボアの処置
WO2010099169A2 (en) * 2009-02-24 2010-09-02 Johns Hopkins University A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
US9474788B2 (en) 2010-05-10 2016-10-25 The J. David Gladstone Institutes Methods for the reactivation of latent HIV using cytosine methylation inhibitors and NF-KB activators
EP2830629A4 (de) * 2012-03-28 2016-01-20 Icahn School Of Medicine Mount Sinai Zusammensetzungen und verfahren zur reaktivierung von latentem immundefizienzvirus
US10106818B2 (en) 2013-08-16 2018-10-23 The J. David Gladstone Institutes Dual-color HIV reporter system for the detection of latently-infected cells
WO2017096161A1 (en) * 2015-12-04 2017-06-08 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus using an akt activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459056A (en) * 1989-08-28 1995-10-17 The United States Of America As Represented By The Department Of Health And Human Services Human T cell line chronically infected with HIV
US5256534A (en) 1991-08-09 1993-10-26 The United States Of America As Represented By The Department Of Health And Human Services CD4+, latently HIV-1-infected hematopoietic progenitor cells
US6025124A (en) 1994-03-03 2000-02-15 The Regents Of The University Of California Marker, method and an assay for detection and monitoring of latency and activation of human immunodeficiency virus
WO1999016891A1 (en) 1997-10-01 1999-04-08 Oregon Health Sciences University Methods of replicating virus in monocyte-derived macrophage cultures

Also Published As

Publication number Publication date
EP1463822A4 (de) 2005-12-28
US7232685B2 (en) 2007-06-19
AU2002361797A1 (en) 2003-07-09
WO2003054160A3 (en) 2003-12-18
AU2002361797A8 (en) 2003-07-09
WO2003054160A2 (en) 2003-07-03
US20030157693A1 (en) 2003-08-21
EP1463822A2 (de) 2004-10-06
US7544467B2 (en) 2009-06-09
EP1463822B1 (de) 2011-10-26
US20090306131A1 (en) 2009-12-10
US20080038716A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
ATE530657T1 (de) Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
DE69634360D1 (de) Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
ATE296349T1 (de) Stoffe und verfahren zur beherrschung der hyperakuten abstossung von menschlichen transplantaten
DE60019111D1 (de) Verfahren zur zellseparation unter verwendung von immunorosetten
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE3280479T2 (de) Rekombinante DNS-Mittel und Verfahren
DE3853735D1 (de) Verfahren zur Gewinnung eines Bruchteils mit Retroviren von Zellen, die Retroviren enthalten.
ATE414783T1 (de) Verfahren zur isolierung von stammzellen
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
DE60320520D1 (de) Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
ATE309267T1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
DE69013730T2 (de) Für ganze Zellen geeigneter Satz und Verfahren zu enzymatischen Bestimmungen.
ATE313622T1 (de) Verfahren zur züchtung von haftenden tierischen zellen
Zhan et al. Modulation of rabbit corneal epithelial cells fate using embryonic stem cell extract
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
MX9603037A (es) Materiales y metodos para manejar rechazo hiperagudo en xenotrasplante humano.
NZ510930A (en) Method of producing a totipotent ungulate cell line and preparing an ungulate fetus
DE29722814U1 (de) Fermenter zur Behandlung einer organischen Masse, insbesondere zur Erzeugung von Biogas
ATE320175T1 (de) Entwicklung einer effektiven gentransfertechnik für das einschleusen von fremd-dns in spermienzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties